Please answer the questions below Ethics in Business QRS became a public company with an initial public offering (IPO) of stock on June 9, 2015, at $12 per share In June 2016, QRS issued 7 5 million additional shares to the public at approximately $33 per share in a seasoned new issue In October 2018, when its stock was trading at about $22 per share, QRS executives announced that the company would spend up to $150 million to reacquire stock from investors On January 8, 2019, The Wall Street Journal reported several analysts were criticizing QRS's executives because the company had issued the shares to the public at a high price ($33) and then were offering to reacquire them at the going stock market price, which was considerably lower than the issue price in 2015 Required Do you think it was inappropriate for QRS to offer to reacquire the stock at a lower stock price in October 2018 Would your answer to requirement 1 be different if QRS had not issued additional stock in June 2016 The above Wall Street Journal article also reported that, in December 2016, QRS executives had purchased, for their own personal investment portfolios, 530,000 shares of stock in the company at the then current price of $13 32 per share If you were an investor, how would you feel about executives buying stock in their own company Would your answer to requirement 3 be different if you also learned that the executives had disposed of nearly 2 5 million shares of QRS stock earlier in the year, when the price was at least $26 08 per share

The Answer is in the image, click to view ...

Answered step by step

Verified Expert Solution

Link Copied!

Question

1 Approved Answer

Posted on Aug 10, 2024

Please answer the questions below. Ethics in Business QRS became a public company with an initial public offering (IPO) of stock on June 9, 2015,

Please answer the questions below.

Ethics in Business

QRS became a public company with an initial public offering (IPO) of stock on June 9, 2015, at $12 per share. In June 2016, QRS issued 7.5 million additional shares to the public at approximately $33 per share in a seasoned new issue. In October 2018, when its stock was trading at about $22 per share, QRS executives announced that the company would spend up to $150 million to reacquire stock from investors. On January 8, 2019, The Wall Street Journal reported several analysts were criticizing QRS's executives because the company had issued the shares to the public at a high price ($33) and then were offering to reacquire them at the going stock market price, which was considerably lower than the issue price in 2015.

Required:

Do you think it was inappropriate for QRS to offer to reacquire the stock at a lower stock price in October 2018?
Would your answer to requirement 1 be different if QRS had not issued additional stock in June 2016?
The above Wall Street Journal article also reported that, in December 2016, QRS executives had purchased, for their own personal investment portfolios, 530,000 shares of stock in the company at the then-current price of $13.32 per share. If you were an investor, how would you feel about executives buying stock in their own company?
Would your answer to requirement 3 be different if you also learned that the executives had disposed of nearly 2.5 million shares of QRS stock earlier in the year, when the price was at least $26.08 per share?